XML 45 R9.htm IDEA: XBRL DOCUMENT v3.19.3
ACQUISITIONS, DIVESTITURES AND OTHER ARRANGEMENTS (Notes)
 9 Months Ended
Sep. 30, 2019
Acquisitions, Divestitures and Other Arrangements [Abstract]  
Mergers, Acquisitions and Dispositions Disclosures [Text Block] DIVESTITURES AND OTHER ARRANGEMENTS

Divestitures

The following table summarizes proceeds, gains or losses and royalty income resulting from divestitures. Revenue and pretax earnings related to all divestitures and assets held-for-sale were not material in all periods presented (excluding divestiture gains or losses).
 
Three Months Ended September 30,
 
Net Proceeds(a)
 
Divestiture Losses/(Gains)
 
Royalty Income
Dollars in Millions
2019
 
2018
 
2019
 
2018
 
2019
 
2018
UPSA Business
$
1,510

 
$
—

 
$
(1,176
)
 
$
—

 
$
—

 
$
—

Diabetes Business
163

 
165

 
—

 
—

 
(171
)
 
(170
)
Erbitux* Business
3

 
59

 
—

 
—

 
—

 
(48
)
Manufacturing Operations
—

 
—

 
1

 
—

 
—

 
—

Mature Brands and Other
7

 
140

 
(4
)
 
(108
)
 
(6
)
 
1

Total
$
1,683

 
$
364

 
$
(1,179
)
 
$
(108
)
 
$
(177
)
 
$
(217
)
 
Nine Months Ended September 30,
 
Net Proceeds(a)
 
Divestiture Losses/(Gains)
 
Royalty Income
Dollars in Millions
2019
 
2018
 
2019
 
2018
 
2019
 
2018
UPSA Business
$
1,510

 
$
—

 
$
(1,160
)
 
$
—

 
$
—

 
$
—

Diabetes Business
491

 
408

 
—

 
—

 
(497
)
 
(497
)
Erbitux* Business
11

 
168

 
—

 
—

 
—

 
(145
)
Manufacturing Operations
3

 
159

 
1

 
—

 
—

 
—

Mature Brands and Other
9

 
212

 
(12
)
 
(178
)
 
(8
)
 
(2
)
Total
$
2,024

 
$
947

 
$
(1,171
)
 
$
(178
)
 
$
(505
)
 
$
(644
)
(a)
Includes royalties received subsequent to the related sale of the asset or business.

UPSA Business

In the third quarter of 2019, the Company sold its UPSA consumer health business, including the shares of UPSA SAS and BMS's assets and liabilities relating to the UPSA product portfolio. The transaction was accounted for as the sale of a business. The UPSA business was treated as a single disposal group held-for-sale as of December 31, 2018.

Assets Held-For-Sale

Manufacturing Operations

In the second quarter of 2019, the Company agreed to sell its manufacturing and packaging facility in Anagni, Italy to Catalent for approximately $50 million. The transaction is expected to close by the end of 2019 subject to regulatory approvals and the satisfaction of certain other customary closing conditions and will be accounted for as a sale of a business. Catalent will provide certain manufacturing and packaging services for the Company for a period of time subsequent to closing. The business was accounted for as held-for-sale and its assets were reduced to the estimated relative fair value resulting in a $113 million impairment charge for the nine months ended September 30, 2019 that was included in Cost of products sold. Assets were reclassified to assets held-for-sale as of September 30, 2019 and included within Prepaid expenses and other. Liabilities were reclassified to liabilities related to assets held-for-sale and included within Accrued and other current liabilities.

The following table summarizes the net assets held-for-sale as of September 30, 2019 and December 31, 2018.
Dollars in Millions
September 30,
2019
 
December 31,
2018
Receivables
$
—

 
$
79

Inventories
7

 
81

Property, plant and equipment
36

 
187

Goodwill
4

 
127

Other
12

 
5

Assets held-for-sale
$
59

 
$
479

 
 
 
 
Accounts payable
$
—

 
$
35

Accrued and other current liabilities
8

 
78

Deferred income taxes
—

 
25

Other liabilities
3

 
14

Liabilities related to assets held-for-sale
$
11

 
$
152

 
 
 
 
Net assets held-for-sale
$
48

 
$
327